至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity

Res Pharm Sci. 2022-07; 
Mohammad Hossein Ataee, Seyed Ali Mirhosseini, Reza Mirnejad, Ehsan Rezaie, Hamideh Mahmoodzadeh Hosseini, Jafar Amani
Products/Services Used Details Operation
Codon Optimization … Rare codon analysis results in the GenScript online program showed the Codon Adaptation Index (CAI), GC content, and Codon Frequency Distribution (CFD) parameters are in the … Get A Quote

摘要

unassigned: The lack of a new effective treatment for small cell lung cancer (SCLC) is an unresolved problem. Due to the new identification of delta-like ligand 3 (DLL3) and its high expression in SCLC patients, the use of DLL3 in target therapy can be effective. The use of bacterial toxins belonging to the ADP-ribosyl transferase toxins family and human enzymes to remove cancerous cells has been effective in the structure of immunotoxins. In this study, single-chain fragment variable of rovalpituzumab antibody fused to granzyme B (Rova-GrB) and PltA of typhoid toxin (Rova-Typh) as immunotoxins were designed, and bioinformatics analysis was done. unassigned: analysis including the physicochemical properties, ev... More

关键词

DLL3, In silico design, Rovalpituzumab, SCLC